P021

Identity: what P021 means

The reviewed compound is P021, also written P-21, P21 or Peptide 021. Those short names are ambiguous: “p21” also denotes an unrelated cell-cycle-regulatory protein. Here the name refers only to the engineered chemical registered in FDA’s Global Substance Registration System (GSRS) as UNII VV8CZC8PAS and CAS 1246751-68-7.

GSRS and PubChem describe formula C27H42N6O8, molecular weight 578.6588 g/mol (rounded by PubChem to 578.7) and PubChem CID 56599151. The literature writes the compound as Ac-DGGL(A)G-NH2 or visually similar forms. That notation means a CNTF-derived four-amino-acid core plus an unnatural terminal adamantylated-glycine modification; it is not an ordinary six-residue natural peptide sequence. For that reason, this page does not force the compound into the wiki’s plain one-letter sequence field.

Why it was engineered

The 2010 design paper and later studies describe P021 as derived from amino-acid residues 148–151 of human ciliary neurotrophic factor (CNTF). Researchers added the terminal adamantylated-glycine group to increase resistance to exopeptidase degradation and lipophilicity. These are design intentions and experimental properties, not proof of oral bioavailability or brain exposure in people.

In cell and rodent models, the proposed biology is indirect: papers report reduced leukemia-inhibitory-factor (LIF) signalling, increased transcription of brain-derived neurotrophic factor (BDNF) and downstream changes including lower glycogen-synthase-kinase-3β activity. Calling P021 a “BDNF mimetic” is therefore misleading. It is not BDNF and has not been shown to reproduce the full clinical biology of BDNF or CNTF.

Evidence landscape: no human intervention identified

The published evidence located through 29 July 2026 consists of cell experiments and animal studies, chiefly mice and rats. The exact ClinicalTrials.gov intervention query for P021 returned 0 studies. Exact searches for “P021” plus CNTF and “Ac-DGGL” also returned 0 registered studies. A broader “P-21 neurotrophic” query returned an unrelated rowing study, illustrating why exact identity review matters.

No published study administering the verified P021 chemical to human participants was identified. Human-derived cell lines and in-vitro human plasma are not human intervention evidence. The evidence level is therefore preclinical, and efficacy, pharmacokinetics, safety and dosing in people remain unestablished.

The literature is also concentrated around an overlapping research programme. Repeated findings in related rodent models increase the amount of preclinical data, but they do not substitute for independent replication or a controlled human trial.

What the preclinical studies show

The preclinical record contains promising findings and an important negative boundary:

• the 2010 paper reported improved learning and memory measures, neurogenesis and maturation of newborn neurons in normal adult mice;
• later rat and 3xTg-AD mouse studies reported effects on cognitive tasks, synaptic markers, neurogenesis and Alzheimer-like amyloid/tau endpoints after prolonged dietary treatment;
• these studies used animal disease models and do not demonstrate prevention or treatment of Alzheimer disease in people;
• a 2024 CDKL5-deficiency study found that P021 restored several deficits in a human neuroblastoma cell model, but chronic treatment in Cdkl5 knockout mice failed to raise BDNF or improve neuroanatomical defects and produced only limited behavioural benefit;
• a 2026 diffusion-MRI paper reports brain-microstructure differences in treated 3xTg-AD mice and now carries an official corrigendum.

The mixed 2024 result is especially useful: a cell-model response did not reliably translate into the living animal. None of these outcomes establishes durable cognitive enhancement, disease modification or “permanent gains” in humans.

Research-integrity update

The evidence map changed in 2026. The 2011 paper “Regional comparison of the neurogenic effects of CNTF-derived peptides and Cerebrolysin in AβPP transgenic mice” is now formally marked as a Retracted Publication, with a retraction notice published in June 2026.

That paper studied the related Peptide 6 and 6A compounds, not P021 itself. It must therefore be excluded both as direct P021 evidence and as reliable support for the surrounding CNTF-peptide/Cerebrolysin narrative. Its retraction does not automatically invalidate every separate P021 paper, but it raises the need for independent replication and careful source-by-source review.

The 2026 P021 diffusion-MRI paper is not retracted; it has a corrigendum. Readers should consult the correction with the original article. These statuses are different and must not be conflated.

Pharmacokinetic and safety limits

No validated human in-vivo pharmacokinetic study was found. The approximately two-hour half-life in PeptideGuide is not supported by a human P021 study. Laboratory stability measurements, animal exposure and duration of a biological endpoint are not interchangeable with a clinical plasma half-life.

No human adverse-event rate, interaction profile, immunogenicity assessment, reproductive-safety dataset or long-term clinical safety study was identified. Reports that prolonged treatment appeared tolerated in particular mouse experiments cannot establish human safety. The identity, purity, dose accuracy and sterility of retail material labelled “P21” are separate, unverified product-quality questions.

There is no regulator-approved regimen. PeptideGuide’s microgram schedules, routes and cycling suggestions are therefore withheld rather than converted into guidance.

Regulatory, anti-doping and source-claim boundaries

FDA GSRS is a substance-identity registry. Its internal record status “approved” means the substance record is approved in that database; it is not FDA approval of P021 as a drug. Exact Drugs@FDA/openFDA searches found no P021 active-ingredient application, and the European Commission’s Union Register dataset dated 27 July 2026 returned no match for P021, P-21, VV8CZC8PAS or the CAS number. No approved P021 medicine or regulator-approved regimen was identified.

The 2026 WADA Prohibited List does not specifically name P021, P-21 or CNTF-derived mimetics. PeptideInfo does not infer a specific WADA class from “unapproved” status alone, and absence of a name is not proof that a substance is permitted. No definitive sport-eligibility flag is assigned here; an athlete needs a current determination from the responsible anti-doping authority.

Country-specific possession, import, supply and human-use rules were not resolved in this wave. Human-use intent can make an unapproved substance an unauthorised medicine even when it is sold as a research reagent.

Bottom line

P021 is a defined experimental chemical with a credible CNTF-derived design and a real body of cell and rodent research. It is not a clinically validated nootropic or Alzheimer treatment. As of 29 July 2026, no human intervention study, approved medicine, human half-life, clinical regimen or human safety profile was identified. The most defensible reading is therefore preclinical and cautious, with the 2024 mixed result, 2026 corrigendum and related-paper retraction kept visible rather than hidden behind older positive animal headlines.